Sirnaomics Ltd., along with its subsidiary RNAimmune, Inc., a leader in mRNA-based vaccine technology, has recently achieved a milestone in their quest to develop advanced therapeutics. The U.S. Food and Drug Administration (FDA) has given the green light for RNAimmune to initiate Phase I clinical trials of RV-1770, an new mRNA vaccine designed to combat the human Respiratory Syncytial Virus (RSV). This approval marks an advancement in the field of RNAi therapeutics, particularly for RNAimmune, which specializes in mRNA vaccines and therapeutics. The trial will involve 162 healthy volunteers, split into two age cohorts, to evaluate the vaccine’s safety and effectiveness across a broad age range. This is a promising development given the substantial global health impact of RSV, which leads to significant hospitalizations annually due to respiratory conditions like pneumonia and bronchiolitis.
The Phase I clinical trial of RV-1770 is designed to assess both the safety and tolerance of the vaccine in adults. Volunteers, ranging from 18 to 79 years old, will receive a single intramuscular dose of the vaccine in one of three dosages: 50 μg, 100 μg, or 200 μg. The study is uniquely structured to include both younger and older adults, ensuring a comprehensive understanding of the vaccine’s effects across different age groups. This approach is particularly crucial as RSV tends to severely affect both very young and elderly populations. The vaccine, a combination of mRNA technology with a proprietary lipid nanoparticle formulation, has already shown promising results in preclinical studies. It has demonstrated effective immune responses and neutralization capabilities against both type A and B strains of RSV in cotton rat studies, indicating its potential as a robust solution against RSV infections.
The development of RV-1770 is a testament to the collaborative efforts of RNAimmune and its partners. Dr. Dong Shen, President and CEO of RNAimmune, emphasized the vaccine’s potential to offer a safe and effective defense against RSV, which poses a significant threat to public health. Dr. Patrick Lu, Chairman of RNAimmune’s board, and Dr. Dewan Zeng, CEO of Zhejiang Innoforce Pharmaceuticals, the vaccine’s CDMO partner, also highlighted the vaccine’s unique mRNA sequence and nanoparticle formulation, noting its exceptional safety and efficacy in preclinical studies. This achievement underscores RNAimmune’s commitment to utilizing advanced mRNA technology to address urgent medical needs, particularly in the realm of respiratory diseases. The success of RV-1770 could pave the way for more innovative solutions in combating various infectious diseases globally.
Related News
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Targeted Lysosomal Degradation of Mutant Huntingtin by Engineered Intrabody Peptide SM3
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Related Services
Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
READ MORE
AAV cGMP Manufacturing
READ MORE
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE